Carcinoma, Ovarian Cancer, Ovarian Diseases, Ovarian Neoplasms
Conditions
Keywords
Clinical Trial, Phase1, Combination Drug Therapy, pharmacokinetics, safety, Ovarian
Brief summary
This is a parallel arm study to evaluate AGS-8M4 administered in combination with chemotherapy in subjects with ovarian cancer. AGS-8M4 will be administered as an IV infusion until disease worsens.
Detailed description
All Subjects will receive AGS-8M4 treatment. Subjects will be enrolled into 1 of 2 treatment arms according to their disease status. A disease assessment will be performed every 8 or 9 weeks (± 3 days) depending on the treatment arm assignment. The assessment will be based both on changes in clinical symptoms, and radiographic images. Subjects without evidence of disease progression may continue to receive treatment based on their original treatment assignment until disease progression or intolerability. A safety follow-up visit will occur 4 weeks after the last dose infusion of AGS-8M4.
Interventions
BIOLOGICALAGS-8M4
IV infusion
DRUGPegylated liposomal doxorubicin (PLD)
IV infusion
DRUGgemcitabine
IV infusion
DRUGcarboplatin
IV infusion
Sponsors
Agensys, Inc.
Astellas Pharma Inc
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subjects with recurrent disease Stage III/IV diagnosis of epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal carcinoma * Subjects with either platinum resistant or platinum sensitive ovarian cancer * At least 14 days of previous cytotoxic chemotherapy and have recovered from all toxicities * Left ventricular ejection fraction (LVEF) equal to or greater than the institutional lower limit of normal as measured by echocardiogram or MUGA (ONLY required for platinum resistant patients)
Exclusion criteria
* Active infection requiring treatment with systemic (intravenous or oral) anti-infectives (antibiotic, antifungal, or antiviral agent) within 72 hours of screening * Use of any investigational drug within 30 days prior to screening * Prior monoclonal antibody therapy other than Avastin * Avastin administration within 90 days of screening * History of thromboembolic events and bleeding disorders ≤ 3 months (e.g.,DVT or PE)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of adverse events | Throughout the treatment |
Secondary
| Measure | Time frame |
|---|---|
| Assessment of PK variables | Treatment Arm A: Weeks 1 and 3 of each cycle. Treatment Arm B: Week 1 of each cycle. In addition, samples will be drawn at the Safety F/U, 2 Month F/U and 3 Month F/U visits. |
| Incidence of anti-AGS-8M4 antibody formation | Treatment Arm A: Day 1 of every other cycle and at Day 15 for the first cycle only. Treatment Arm B: Day 1 of every other cycle. In addition, samples will be drawn at the Safety F/U, 2 Month F/U and 3 Month F/U visits. |
| Changes in tumor status per RECIST | Treatment Arm A: Every 8 weeks. Treatment Arm B: Every 9 weeks. |
| Change in CA-125 levels | Treatment Arm A: Day 1 and Day 15 of each cycle. Treatment Arm B: Day 1 of each cycle. In addition, samples will be drawn at the Safety F/U. |
Countries
United States
Outcome results
None listed